We are tackling the most
pressing questions in Medicine
300 million people are waiting for a cure that doesn't yet exist.
Because understanding the complexity of human biology is beyond the limits of human intelligence.
01
The world's largest network of AI-ready patient data
02
Our autonomous AI scientist: K Pro
03
Organoids and chemistry wet lab validation
We built the first solution that automates AI in biology. Powered by a unique combination of three pillars.
Intelligence is only as good as what it learns from.
Ours learns from 25 million patients’ data across 840 hospitals: multimodal, longitudinal and ready for AI.
K Pro's unique architecture and harness bring together multiple agents, tools and skills shaped by our network of 150 KOLs.
They work in parallel as an autopilot or co-pilot across the full drug development pipeline.
K Pro's best hypotheses are validated via our biomedical experts and wet lab. Each insight feeds back into K Pro as a reusable workflow, taking research programs from data to drugs.
Trusted by top partners
We work with the world's largest biopharma and technology companies.
OPEN QUESTIONS
Tackling the most pressing questions in medicine
Discover the progress we are making towards solving these questions, from discovering novel biology to bringing new assets into clinical trials. Explore the medical questions below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Projects
Oncology and Immunotherapy
Which patients respond to the newest cancer drugs, which targets to hit next, and why tumors resist.
Explore progress
Which ADC mono- and multi-specifics can target all malignant cancer subclones in a the largest proportion of patients in a ovarian cancer?
Which ADC mono- and multi-specifics can target all malignant cancer subclones in a the largest proportion of patients in bladder cancer?
Which ADC mono- and multi-specifics can target all malignant cancer subclones in a the largest proportion of patients in a given cancer?
Which drugs combined to KRAS inhibitors can increase response in cancer?
Which unrecognized pathways drive treatment resistance in glioblastoma, and which can be targeted?
What distinguishes exceptional responders to TROP2 antibody–drug conjugates in non-small cell lung cancer?
Which biomarkers predict response, resistance and toxicity to enfortumab vedotin plus pembrolizumab in bladder cancer?
Which bladder cancer patients can safely avoid radical cystectomy without compromising survival?
Which DLBCL patients can be treated with immunotherapy and targeted therapy instead of chemotherapy?
X
Projects
Neuroscience and Neurodegeneration
New routes into Alzheimer's, ALS and neurodegeneration beyond the current targets.
Explore progress
Which pathways beyond NLRP3 could yield more effective treatments for neurodegenerative disease?
Which strategies beyond antisense therapy can improve outcomes in SOD1-associated ALS?
Which spatially resolved targets could slow Alzheimer's disease without disrupting sleep or normal brain function?
X
Projects
Cardiology and Autonomic Disease
Catching cardiac amyloid before it does irreversible damage, and finding the distinct forms of heart failure and POTS hiding under one name.
Explore progress
Can blood biomarkers and imaging detect transthyretin amyloid cardiomyopathy before irreversible damage occurs?
Which biological subtypes of POTS exist, and which therapeutic targets correspond to each?
X
Projects
Stroke
Why strokes happen, read directly from the clot itself.
Explore progress
Why do strokes occur, and what biology underlies their different mechanisms?
Can a first-of-its-kind biopsy of the human clot redefine the molecular landscape of stroke
X
Projects
Pulmonary and Cardiometabolic Disease
Why only some mutation carriers scar, the subtypes of severe COPD, and whether lung ageing can be slowed.
Explore progress
Why do only some carriers of telomerase mutations develop pulmonary fibrosis, and what determines progression?
Which biological subtypes and associated pathways define COPD with severe pulmonary hypertension?
What drives lung ageing and fibrosis, and which targets could slow or reverse it?
X
Projects
Obesity and metabolic disease
Why weight-loss treatment works for some people and not others, and what predicts long-term outcomes.
Explore progress
What molecular signature marks obesity that resists weight-loss treatment, and what therapeutic follows from it?
Is there an early biomarker that predicts long-term outcomes, including mortality, after weight-loss treatment?
X
Projects
Ageing, Muscle and Regeneration
How tissues are built and repaired early in life, and how to prevent the loss of muscle that turns old age into frailty.
Explore progress
Which interventions can prevent or reverse sarcopenia by restoring muscle regeneration, without systemic toxicity?
Which macrophage-related mechanisms of tissue development and repair are specific to pregnancy and early childhood vs adulthood?
Join us
Be part of the vision
For frontier labs and investors who want to join us in this mission.
K Pro
Put the AI Scientist to work on your questions
K Pro brings the same AI Scientist to your drug R&D:
Join four of the world's largest pharma companies, AstraZeneca, Sanofi, Servier and Boehringer Ingelheim, using it today.
Get in touch for a Demo
Discover how K Pro can transform your drug discovery and development. Connect with our team to explore how we can support your specific needs.
Book a Demo
